Assenagon Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Assenagon Asset Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-653	Closed	-$13.8K	–	1485
2023 Q2	$13.8K	Buy	+653	New	+$20.1K	﹤0.01%	1313
2023 Q1	–	Sell	-21,092	Closed	-$747K	–	1531
2022 Q4	$747K	Buy	21,092 +613	+3%	+$73.6K	﹤0.01%	1104
2022 Q3	$4.63M	Sell	20,479 -759	-4%	-$187K	0.02%	505
2022 Q2	$4.01M	Buy	21,238 +873	+4%	+$176K	0.01%	610
2022 Q1	$5.07M	Buy	20,365 +12,914	+173%	+$2.04M	0.01%	531
2021 Q4	$1.16M	Buy	+7,451	New	+$1.44M	﹤0.01%	983
2021 Q2	–	Sell	-13,057	Closed	-$3.47M	–	1453
2021 Q1	$3.47M	Sell	13,057 -5,449	-29%	-$1.72M	0.01%	587
2020 Q4	$6.82M	Hold	18,506	–	–	0.03%	310
2020 Q3	$4.52M	Buy	18,506 +16,314	+744%	+$5.07M	0.03%	354
2020 Q2	$631K	Buy	+2,192	New	+$646K	﹤0.01%	940
2019 Q3	–	Sell	-14,806	Closed	-$4.71M	–	1114
2019 Q2	$4.71M	Buy	+14,806	New	+$5.13M	0.04%	303

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management's EIGR Position: Q3 2023 in Review

Assenagon Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 653 shares — an estimated $13.8K sold.

Assenagon Asset Management first reported a position in EIGR in Q2 2019 and held it in 11 quarters. The position peaked at $6.82M in Q4 2020. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.

Assenagon Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Assenagon Asset Management sold 653 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $13.8K.
Assenagon Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 11 quarters.
Assenagon Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $6.82M in Q4 2020.
51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.

Based on Assenagon Asset Management's 13F filing for Q3 2023, filed 6 Nov 2023.